Heron Therapeutics (NASDAQ:HRTX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at Needham & Company LLC in a note issued to investors on Wednesday, Benzinga reports. They presently have a $5.00 price target on the biotechnology company's stock. Needham & Company LLC's price target would indicate a potential upside of 164.55% from the company's current price.
Separately, Rodman & Renshaw started coverage on Heron Therapeutics in a report on Thursday, June 13th. They set a "buy" rating and a $7.00 target price on the stock.
Check Out Our Latest Research Report on Heron Therapeutics
Heron Therapeutics Stock Down 3.6 %
Shares of NASDAQ HRTX traded down $0.07 during midday trading on Wednesday, reaching $1.89. The company had a trading volume of 3,603,777 shares, compared to its average volume of 2,553,995. Heron Therapeutics has a one year low of $0.50 and a one year high of $3.93. The firm's fifty day moving average price is $2.22 and its 200-day moving average price is $2.76. The stock has a market cap of $284.73 million, a PE ratio of -3.10 and a beta of 1.80.
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.02). The company had revenue of $36.02 million during the quarter, compared to the consensus estimate of $35.35 million. During the same quarter in the previous year, the company posted ($0.35) EPS. As a group, equities research analysts expect that Heron Therapeutics will post -0.1 EPS for the current year.
Hedge Funds Weigh In On Heron Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HRTX. nVerses Capital LLC purchased a new stake in shares of Heron Therapeutics in the 2nd quarter worth $27,000. Headlands Technologies LLC bought a new stake in shares of Heron Therapeutics during the first quarter valued at approximately $30,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Heron Therapeutics during the first quarter valued at approximately $32,000. Victory Capital Management Inc. increased its holdings in Heron Therapeutics by 30.2% during the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company's stock valued at $34,000 after buying an additional 4,617 shares during the period. Finally, HB Wealth Management LLC purchased a new position in Heron Therapeutics during the second quarter valued at approximately $35,000. 80.01% of the stock is owned by institutional investors.
About Heron Therapeutics
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Recommended Stories
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
